Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| EscitalopramNCT00423969 | Indiana UniversityPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-01-18 |
| GalantamineNCT00423969 | Indiana UniversityPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-01-18 |
| sumaniroleNCT00036205 | PfizerPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2007-01-18 |
| Penicillin versus cefuroxim per osNCT00261742 | University Children's Hospital BaselPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-01-17 |
| Macugen (pegaptanib sodium)NCT00134667 | Eyetech PharmaceuticalsPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-01-15 |
| Photodynamic Therapy (PDT) with Visudyne (verteporfin)NCT00134667 | Eyetech PharmaceuticalsPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-01-15 |
| Pegaptanib sodiumNCT00312351 | Eyetech PharmaceuticalsPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-01-15 |
| RituximabNCT00127569 | French National Agency for Research on AIDS and Viral HepatitisPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-01-12 |
| tocopherolNCT00119119 | French National Agency for Research on AIDS and Viral HepatitisPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-01-12 |
| pentoxyphillineNCT00119119 | French National Agency for Research on AIDS and Viral HepatitisPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-01-12 |
| GPX-100 (13-deoxydoxorubicin)NCT00123877 | Gem PharmaceuticalsPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-01-09 |
| Risperdal Long Acting Injectable Antipsychotic MedicationNCT00287027 | National Alliance on Mental Illness New HampshirePhase unknown | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-01-05 |
| Estrogen/progestin therapyNCT00000430 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)PHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-01-04 |
| AlendronateNCT00000430 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)PHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-01-04 |
| sertraline or amitriptylineNCT00325000 | German Research FoundationNA | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2006-12-20 |
| Subcutaneous immunotherapy - Recombinant birch pollenNCT00410930 | Stallergenes GreerPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2006-12-19 |
| ATG-Sirolimus-TacrolimusNCT00409461 | Universitair Ziekenhuis BrusselNA | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2006-12-11 |
| MST-997NCT00088647 | Wyeth is now a wholly owned subsidiary of PfizerPHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2006-12-08 |
| MST-997NCT00277836 | Wyeth is now a wholly owned subsidiary of PfizerPHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-12-08 |
| Comparator: diclofenac, placeboNCT00140933 | Merck Sharp & Dohme LLCPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2006-12-05 |
| MK0966; rofecoxibNCT00140933 | Merck Sharp & Dohme LLCPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2006-12-05 |
| intracoronary infusion of progenitor cellsNCT00289822 | Johann Wolfgang Goethe University HospitalPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-11-30 |
| veliflapon (DG-031)NCT00353067 | deCODE geneticsPHASE3 | SUSPENDED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2006-11-29 |
| Virosome-formulated synthetic peptides (malaria vaccine)NCT00400101 | Swiss Tropical & Public Health InstitutePHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-11-16 |
| repeated intake of fermented milk followed by a single oral dose of an ACE inhibitorNCT00399737 | Assistance Publique - Hôpitaux de ParisPHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-11-15 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |